Allergy Immunotherapy is an allergy treatment process that involves administering small quantities of allergens into your body and then building up doses slowly over a while until the patient develops immunity. Two types of immunotherapy therapies are available in the market, such as subcutaneous immunotherapy (SCIT), also called allergy shots, and sublingual immunotherapy (SLIT). Individuals with symptoms of allergy and do not respond to conventional medical treatments are the potential targets for allergen immunotherapy. When the trigger for allergens is established, an extract of that material is prepared. The mode of delivery depends on what form of immunotherapy patients are receiving. The Allergy Immunotherapy market is expected to witness huge growth due to the increasing prevalence of allergic disorders, and rising preference for immunologic therapies due to efficacy and cost-effectiveness of treatment is anticipated to drive the global Allergy Immunotherapies market growth.
ALK-Abelló A/S, Stallergenes Greer, and AIMMUNE THERAPEUTICS, INC. – Notable Market Players in Allergy Immunotherapies Market.
Market leaders working in the market have offered several organic growth strategies in the allergy immunotherapies market. The allergy immunotherapies market majorly consists of the players such as ALK-Abelló A/S, AIMMUNE THERAPEUTICS, INC., LETIPharma, Stallergenes Greer, HAL Allergy B.V., Anergis, DBV Technologies, Dermapharm Holding, Allergy Therapeutics, ASIT biotech among others. Several in organic approaches, such as mergers & acquisitions and collaboration in the allergy immunotherapies market, have occurred in the positive growth of the market. Mergers & Acquisitions help the company to strengthen its revenue, which enables the company to hold a robust place in the market. Furthermore, utilizing development projects, it is easy to venture into untapped markets and use the possibilities being offered.
Below is the list of the growth strategies done by the players operating in the Allergy Immunotherapy market:
| Year | News |
| March 2020 | Dermapharm Holding SE acquired Allergopharma, a part of Merck KGaA. Allergopharma is specialized in the subcutaneous immunotherapy of allergies and offers a wide range of high-dose hypoallergenic products such as allergoids and a large variety of allergens for diagnostics. |
| July 2020 | Anergis and Virometix AG entered into a research collaboration for the application of synthetic virus-like particles for the Ultra-Fast Allergy Immunotherapy technology that based on Contiguous Overlapping Peptides (COPs) |
| January 2020 | Aimmune Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) approval for PALFORZIA, the first approved treatment for patients with peanut allergy. |
